Zacks Research Issues Pessimistic Estimate for GSK Earnings

GSK PLC Sponsored ADR (NYSE:GSK) – Zacks Research lowered their Q1 2026 earnings estimates for GSK in a note issued to investors on Wednesday, November 19th. Zacks Research analyst Team now forecasts that the pharmaceutical company will earn $1.13 per share for the quarter, down from their prior estimate of $1.15. The consensus estimate for GSK’s current full-year earnings is $4.14 per share. Zacks Research also issued estimates for GSK’s FY2026 earnings at $4.71 EPS, Q1 2027 earnings at $1.13 EPS and Q3 2027 earnings at $1.41 EPS.

Other equities analysts also recently issued research reports about the company. Wall Street Zen raised GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 5th. Cfra set a $53.00 price objective on shares of GSK in a research note on Thursday, October 30th. Jefferies Financial Group reiterated a “buy” rating on shares of GSK in a report on Monday, October 27th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of GSK in a research report on Thursday. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $44.13.

GSK Stock Up 2.2%

Shares of NYSE GSK opened at $47.14 on Friday. GSK has a 52-week low of $31.72 and a 52-week high of $48.69. The firm has a market capitalization of $95.71 billion, a price-to-earnings ratio of 13.32, a PEG ratio of 1.90 and a beta of 0.50. The stock has a 50 day moving average price of $44.23 and a 200 day moving average price of $40.75. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, October 29th. The pharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.22. The company had revenue of $11.35 billion during the quarter, compared to analysts’ expectations of $8.21 billion. GSK had a net margin of 17.16% and a return on equity of 51.07%. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.50 EPS. GSK has set its FY 2025 guidance at 4.730-4.810 EPS.

GSK Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 8th. Stockholders of record on Friday, November 14th will be given a dividend of $0.4171 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $1.67 dividend on an annualized basis and a dividend yield of 3.5%. GSK’s dividend payout ratio is presently 46.05%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in GSK. Dodge & Cox increased its position in GSK by 14.9% during the 1st quarter. Dodge & Cox now owns 78,651,833 shares of the pharmaceutical company’s stock valued at $3,046,972,000 after buying an additional 10,210,921 shares in the last quarter. Acadian Asset Management LLC increased its holdings in shares of GSK by 201.9% during the first quarter. Acadian Asset Management LLC now owns 3,982,324 shares of the pharmaceutical company’s stock valued at $154,244,000 after acquiring an additional 2,663,270 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of GSK during the first quarter valued at about $67,267,000. Fisher Asset Management LLC raised its position in shares of GSK by 4.4% in the 2nd quarter. Fisher Asset Management LLC now owns 31,338,405 shares of the pharmaceutical company’s stock valued at $1,203,395,000 after purchasing an additional 1,306,590 shares during the last quarter. Finally, Clark Capital Management Group Inc. boosted its stake in GSK by 138.2% in the 1st quarter. Clark Capital Management Group Inc. now owns 1,565,735 shares of the pharmaceutical company’s stock worth $60,657,000 after purchasing an additional 908,284 shares in the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.